Pharma manufacturing news in brief
pharmafile | June 19, 2012 | News story | Manufacturing and Production |Â Â BioWa, Cytovance Biologics, DHL, Dalton Pharma Services, Lonza, Particle Sciences, RecipharmÂ
DHL opens up a facility in Mumbai, Recipharm invests in French filling plant, plus updates from Dalton Pharma Services, Particle Sciences, Lonza/BioWa and Cytovance Biologics.
DHL has opened a 56,000 sq. m. distribution and warehousing operation in Mumbai, India, to serve the country’s life sciences and healthcare sector. The logistics specialist said the move was part of a strategy to extend its services into emerging markets around the world. The Mumbai facility will also handle clinical trial services. “Looking to 2015 and beyond, India, China and other emerging markets are expected to be the key drivers of growth in the pharmaceutical and medical device sectors”, said Angelos Orfanos, global head of life sciences and healthcare, at DHL Customer Solutions & Innovation.
Swedish contract development and manufacturing organisation (CDMO) Recipharm says it has expanded the injectable drug filling capacity of its facility in Monts, France, thanks to a €600,000 investment which includes a Dara cartridge filling machine. The unit can fill cartridges at a rate of up to 7,200 per hour and will allow Recipharm to “not only reduce lead times but also increase reliability and flexibility” for its customers.
Dalton Pharma Services has entered into a manufacturing services agreement with Australia’s Clarity Pharmaceuticals in which it will provide Good Manufacturing Practice (GMP) chemistry manufacturing, scale-up, aseptic fill/finish services and analytical support for Clarity’s PET-based companion diagnostics and radio-immunotherapeutics development programme.
Drug delivery specialist Particle Sciences has added new thin-film coating capabilities for Good Manufacturing Practice (GMP) preparation of polymer film-based drug products from liquid formulations, thanks to investment in new equipment. The company said it is seeing an increase demand for thin-film-based products such as transdermal drug-eluting patches and rapidly-dissolving oral strips, according to Garry Gwozdz, Particle Sciences’ director of formulation services.
Five Prime Therapeutics of the US has signed agreements with BioWa and Lonza in order to make use of a proprietary cell line for the R&D and production of multiple antibodies in its oncology pipeline. The deal centres on Lonza and BioWa’s POTELLIGENT CHOK1SV, a high-yield cell line that can be used to produce antibodies with enhanced antibody dependent cellular cytotoxicity (ADCC) that can exert potent cytotoxic effects, even when the target antigen is present in low concentrations.
Cytovance Biologics has been awarded a contract to develop the manufacturing process for BiologicsMD’s PTH-CBD, a parathyroid hormone-based therapy for osteoporosis which was backed by a $2.3 million grant from the US Department of Defense last year. Cytovance Biologics will help the biotech company develop a manufacturing process for material that will be used for toxicology studies and Phase I clinical testing.
Phil Taylor
Related Content
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
Recipharm designates Germany site as Centre of Excellence
The multi-product facility recently underwent significant renovations
Strategic alliance announced between Recipharm and Exela
Recipharm and Exela have announced that they have entered into an exclusive strategic alliance. The …
